Biosyent Inc is a growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products.

BioSyent Releases Results for Fourth Quarter and Full Year 2018

Nov 21, 2018

BioSyent Releases Results for Third Quarter and First Nine Months of 2018

More Press Releases

Biosyent Inc is a growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn and Tibella.

Go Deeper

AI Powered

Interactive Chart

Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.